<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Bioinformatics</journal-id><journal-id journal-id-type="iso-abbrev">BMC Bioinformatics</journal-id><journal-title-group><journal-title>BMC Bioinformatics</journal-title></journal-title-group><issn pub-type="epub">1471-2105</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5960098</article-id><article-id pub-id-type="publisher-id">2185</article-id><article-id pub-id-type="doi">10.1186/s12859-018-2185-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Methodology Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Robust joint score tests in the application of DNA methylation data analysis </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xuan</given-names></name><address><email>lixuan@mathstat.yorku.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8606-570X</contrib-id><name><surname>Fu</surname><given-names>Yuejiao</given-names></name><address><email>yuejiao@mathstat.yorku.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiaogang</given-names></name><address><email>stevenw@mathstat.yorku.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Weiliang</given-names></name><address><email>stwxq@channing.harvard.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9430</institution-id><institution-id institution-id-type="GRID">grid.21100.32</institution-id><institution>Department of Mathematics and Statistics, York University, </institution></institution-wrap>4700 Keele Street, Toronto, M3J1P3 Canada </aff><aff id="Aff2"><label>2</label>Channing Division of Network Medicine, Brigham and Women’s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, 02115 USA </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>19</volume><elocation-id>174</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>2</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>© The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Recently differential variability has been showed to be valuable in evaluating the association of DNA methylation to the risks of complex human diseases. </plain></SENT>
<SENT sid="3" pm="."><plain>The statistical tests based on both differential methylation level and differential variability can be more powerful than those based only on differential methylation level. </plain></SENT>
<SENT sid="4" pm="."><plain>Anh and Wang (2013) proposed a joint score test (AW) to simultaneously detect for differential methylation and differential variability. </plain></SENT>
<SENT sid="5" pm="."><plain>However, AW’s method seems to be quite conservative and has not been fully compared with existing joint tests. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="6" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>We proposed three improved joint score tests, namely iAW.Lev, iAW.BF, and iAW.TM, and have made extensive comparisons with the joint likelihood ratio test (jointLRT), the Kolmogorov-Smirnov (KS) test, and the AW test. </plain></SENT>
<SENT sid="8" pm="."><plain>Systematic simulation studies showed that: 1) the three improved tests performed better (i.e., having larger power, while keeping nominal Type I error rates) than the other three tests for data with outliers and having different variances between cases and controls; 2) for data from normal distributions, the three improved tests had slightly lower power than jointLRT and AW. </plain></SENT>
<SENT sid="9" pm="."><plain>The analyses of two Illumina HumanMethylation27 data sets GSE37020 and GSE20080 and one Illumina Infinium MethylationEPIC data set GSE107080 demonstrated that three improved tests had higher true validation rates than those from jointLRT, KS, and AW. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="10" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>The three proposed joint score tests are robust against the violation of normality assumption and presence of outlying observations in comparison with other three existing tests. </plain></SENT>
<SENT sid="12" pm="."><plain>Among the three proposed tests, iAW.BF seems to be the most robust and effective one for all simulated scenarios and also in real data analyses. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="13" pm="."><plain>Electronic supplementary material </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>The online version of this article (10.1186/s12859-018-2185-3) contains supplementary material, which is available to authorized users. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group xml:lang="en"><title>Keywords</title><kwd>Methylation data</kwd><kwd>Joint score tests</kwd><kwd>Variability</kwd></kwd-group></SecTag><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000038</institution-id><institution>Natural Sciences and Engineering Research Council of Canada</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000038</institution-id><institution>Natural Sciences and Engineering Research Council of Canada</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec id="Sec1"><title><text><SENT sid="15" pm="."><plain>Background </plain></SENT>
</text></title><p><text><SENT sid="16" pm="."><plain>DNA methylation is an epigenetic mechanism that regulates gene expression without changing genetic codes. </plain></SENT>
<SENT sid="17" pm="."><plain>Usually, DNA methylation inhibits the expression of its nearby gene by adding a methyl group to the fifth carbon atom of a cytosine ring. </plain></SENT>
<SENT sid="18" pm="."><plain>Since it is a reversible biological process, DNA methylation is now considered as a potential therapeutic target in cancer treatment due to its ability to inhibit the expression of oncogenes which can transform a cell into a tumor cell in certain circumstances. </plain></SENT>
</text></p><p><text><SENT sid="19" pm="."><plain>One major goal in the analysis of methylation data is to identify disease-associated CpG sites. </plain></SENT>
<SENT sid="20" pm="."><plain>Many analyses in the past have been focused on the difference of average or mean methylation levels between the disease and the control group. </plain></SENT>
<SENT sid="21" pm="."><plain>However, it has not been a common practice in the classical statistical analysis to test a hypothesis of equal variances since the difference of population means between the disease and control group is normally the inferential interest. </plain></SENT>
<SENT sid="22" pm="."><plain>Recently, some evidence suggests that the epigenetic variation is also a very important intrinsic characteristic associated with certain diseases [1–6]. </plain></SENT>
<SENT sid="23" pm="."><plain>These papers in DNA methylation analyses showed that differentially variable DNA methylation marks are biologically relevant to the disease of interest since the genes regulated by these marks are enriched in the biological pathways that have been found important to the disease of interest. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>Although there are more than 50 statistical tests for equal variance [7], several new methods have been proposed especially for the analysis of DNA methylation data [2, 8]. </plain></SENT>
<SENT sid="25" pm="."><plain>We recently compared these new methods [4] and proposed three improved equal variance tests based on the score test of logistic regression [6]. </plain></SENT>
<SENT sid="26" pm="."><plain>Since both mean and variance are biologically meaningful in DNA methylation analysis, it is logical to simultaneously test for equal mean and equal variance. </plain></SENT>
<SENT sid="27" pm="."><plain>The joint likelihood ratio test (jointLRT) and the two-sample Kolmogorov-Smirnov (KS) test are two traditional methods for this task. </plain></SENT>
<SENT sid="28" pm="."><plain>Recently Anh and Wang (2013) [8] proposed a new joint test based on logistic regression (AW), which is essentially a quadratic form of a vector of two tests. </plain></SENT>
<SENT sid="29" pm="."><plain>One of them is to test for equal means; the other is to test for equal variances. </plain></SENT>
<SENT sid="30" pm="."><plain>However, they did not provide the asymptotic distribution of their test statistic nor the comparison of their joint test with jointLRT or KS that are the benchmark tests in the statistical literature. </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>In this article, we derived the asymptotic distribution of the AW joint test statistic and made comprehensive comparisons between AW, jointLRT and KS tests. </plain></SENT>
<SENT sid="32" pm="."><plain>Although a normal distribution is usually assumed for methylation data, the violation of normality assumption and presence of outlying points can often be observed in the analysis of real data. </plain></SENT>
<SENT sid="33" pm="."><plain>Bi-modal distributions are also encountered frequently in practice. </plain></SENT>
<SENT sid="34" pm="."><plain>To improve the power and robustness of the AW joint test, we proposed three tests based on absolute deviation from mean (iAW.Lev), median (iAW.BF) and trimmed mean (iAW.TM) respectively. </plain></SENT>
</text></p><p><text><SENT sid="35" pm="."><plain>Results from our simulation studies suggest that the three improved tests are robust in skewed distributions and (unimodal) distributions with outliers. </plain></SENT>
<SENT sid="36" pm="."><plain>Among the three improved tests, iAW.BF is the most robust in mixtures of two normal distributions and also in other scenarios. </plain></SENT>
<SENT sid="37" pm="."><plain>Results of real data analyses presented that iAW.BF and iAW.TM performed significantly better than AW, jointLRT, and KS. </plain></SENT>
<SENT sid="38" pm="."><plain>Although iAW.Lev works well in the simulation setting, it does not seem to be very stable in terms of the proportion of true validation in real data analyses. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="Sec2"><title><text><SENT sid="39" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="Sec3"><title><text><SENT sid="40" pm="."><plain>Justification for Ahn and Wang’s joint score test </plain></SENT>
</text></title><p><text><SENT sid="41" pm="."><plain>Ahn and Wang (2013) [8] proposed a joint score test to detect methylation marks relevant to a disease. </plain></SENT>
<SENT sid="42" pm="."><plain>Their approach tests for homogeneity of means and variances simultaneously. </plain></SENT>
<SENT sid="43" pm="."><plain>Since Ahn and Wang (2013) [8] did not provide a detailed theoretical proof for the asymptotic distribution of this joint score test, we now fill this gap in theory. </plain></SENT>
</text></p><p><text><SENT sid="44" pm="."><plain>Let Xi and Yi denote the methylation value and the corresponding disease status of subject i, where i=1,2,…,n, with n=n0+n1, n0 is the number of the non-diseased subjects (controls, Yi=0) and n1 is the number of the diseased subjects (cases, Yi=1). </plain></SENT>
<SENT sid="45" pm="."><plain>To detect methylation loci that are relevant to a disease based on means and variances, the corresponding hypothesis is formulated as H0:μ0=μ1 and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\sigma _{0}^{2}=\sigma _{1}^{2}$\end{document}σ02=σ12 versus H1:μ0≠μ1 or \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\sigma _{0}^{2} \neq \sigma _{1}^{2}$\end{document}σ02≠σ12, in which μ0 and μ1 are means of methylation levels for controls and cases, respectively, and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\sigma _{0}^{2}$\end{document}σ02 and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\sigma _{1}^{2}$\end{document}σ12 are the corresponding variances. </plain></SENT>
</text></p><p><text><SENT sid="46" pm="."><plain>Instead of directly testing the above hypothesis, Ahn and Wang (2013) [8] proposed to test H0′:β1=β2=0 versus Ha′:β1≠0 or β2≠0, where β1 and β2 are the regression coefficients of the following logistic regression: 1\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$\begin{array}{@{}rcl@{}} logit\left[Pr(Y_{i}=1|x_{i},z_{i})\right]=\beta_{0}+\beta_{1} x_{i}+\beta_{2} z_{i}, \end{array} $$ \end{document}logitPr(Yi=1|xi,zi)=β0+β1xi+β2zi, </plain></SENT>
</text></p><p><text><SENT sid="47" pm="."><plain>and zi is the within-group squared deviation for subject i, which is defined as 2\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$ z_{i}=\left\{\begin{array}{ll} \left(x_{i}-\bar{x}_{1}\right)^{2}, \text{if } Y_{i}=1,\\ \left(x_{i}-\bar{x}_{0}\right)^{2}, \text{if } Y_{i}=0, \end{array}\right. $$ \end{document}zi=xi−x¯12,ifYi=1,xi−x¯02,ifYi=0, </plain></SENT>
</text></p><p><text><SENT sid="48" pm="."><plain>and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\bar {x}_{1}=\sum _{i=1}^{n}x_{i}I\left [y_{i}=1\right ]/n_{1}$\end{document}x¯1=∑i=1nxiIyi=1/n1 and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\bar {x}_{0}=\sum _{i=1}^{n}x_{i}I \left [y_{i}=0\right ]/n_{0}$\end{document}x¯0=∑i=1nxiIyi=0/n0 are the sample means for cases and controls. </plain></SENT>
</text></p><p><text><SENT sid="49" pm="."><plain>The AW test statistic \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$T=\mathbf {U}^{T}\widehat {\mathbf {\Sigma }}^{-1}\mathbf {U}$\end{document}T=UTΣ^−1U is a quadratic form of two score statistics U1 and U2 for the above logistic regression, where U=(U1,U2)T, 3\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$ \begin{aligned} U_{1}=&amp;\sum_{i=1}^{n}x_{i}\left(y_{i} - \bar{y}\right),\\ U_{2}=&amp;\sum_{i=1}^{n}z_{i}\left(y_{i} - \bar{y}\right), \end{aligned} $$ \end{document}U1=∑i=1nxiyi−y¯,U2=∑i=1nziyi−y¯, </plain></SENT>
</text></p><p><text><SENT sid="50" pm="."><plain>and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\widehat {\mathbf {\Sigma }}$\end{document}Σ^ is the estimate of the covariance matrix Cov(U). </plain></SENT>
</text></p><p><text><SENT sid="51" pm="."><plain>Under H0′, the estimated covariance matrix \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\widehat {\mathbf {\Sigma }}$\end{document}Σ^ has the following form: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$\widehat{\mathbf{\Sigma}}=n\bar{y}\left(1-\bar{y}\right) \left(\begin{array}{cc} \hat{\sigma}_{x}^{2}&amp;\hat{\sigma}_{xz}\\ \hat{\sigma}_{xz}&amp;\hat{\sigma}_{z}^{2} \end{array} \right), $$ \end{document}Σ^=ny¯1−y¯σ^x2σ^xzσ^xzσ^z2, where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\hat {\sigma }_{x}^{2}=\sum _{i=1}^{n}(x_{i}-\bar {x})^{2}/n$\end{document}σ^x2=∑i=1n(xi−x¯)2/n and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\hat {\sigma }_{z}^{2}=\sum _{i=1}^{n}(z_{i}-\bar {z})^{2}/n$\end{document}σ^z2=∑i=1n(zi−z¯)2/n are the sample variances for xi and zi, and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\hat {\sigma }_{xz}=\sum _{i=1}^{n} (x_{i}-\bar {x})(z_{i}-\bar {z})/n$\end{document}σ^xz=∑i=1n(xi−x¯)(zi−z¯)/n is the sample covariance between xi and zi. </plain></SENT>
</text></p><p><text><SENT sid="52" pm="."><plain>Note that in logistic regression (1), the random variables are yi, while xi and zi are fixed (i.e., non-random). </plain></SENT>
<SENT sid="53" pm="."><plain>Hence, the (asymptotic) distributions of the U1, U2, and T do not depend on the distributions of xi and zi. </plain></SENT>
<SENT sid="54" pm="."><plain>In this sense, we can say that the AW test statistic T is theoretically robust against the violation of the normality assumption for the predictors xi and zi. </plain></SENT>
</text></p><p><text><SENT sid="55" pm="."><plain>Dobson (1990) [9] showed that \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\mathbf {U} \stackrel {H_{0}'}{\rightarrow } N(\mathbf {0},Cov(\mathbf {U}))$\end{document}U→H0′N(0,Cov(U)). </plain></SENT>
<SENT sid="56" pm="."><plain>When the sample size is large, the asymptotic distribution of T is \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\chi _{2}^{2}$\end{document}χ22 under H0′, based on the Law of Large Numbers and the relationship between the multivariate normal distribution and the chi-squared distribution. </plain></SENT>
<SENT sid="57" pm="."><plain>Ascribed to limited space, the complete proof is included in the Additional file 1. </plain></SENT>
</text></p><sec id="Sec4"><title><text><SENT sid="58" pm="."><plain>Three improved joint score tests </plain></SENT>
</text></title><p><text><SENT sid="59" pm="."><plain>Since the within-group squared deviation in (2) might not be very robust, we propose three improved joint score tests. </plain></SENT>
</text></p><p><text><SENT sid="60" pm="."><plain>In the first improved joint score test (denoted as iAW.Lev), we replace the within-group squared deviation by within-group absolute deviation [10]: 4\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$\begin{array}{@{}rcl@{}} z_{i}^{*}= \left\{ \begin{array}{ll} |x_{i}-\bar{x}_{1}|, \text{if } Y_{i}=1,\\ |x_{i}-\bar{x}_{0}|, \text{if } Y_{i}=0. \end{array} \right. \end{array} $$ \end{document}zi∗=|xi−x¯1|,ifYi=1,|xi−x¯0|,ifYi=0. </plain></SENT>
</text></p><p><text><SENT sid="61" pm="."><plain>For the logistic regression \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$logit \left [Pr \left (Y_{i}=1 |x_{i},z_{i}^{*}\right)\right ]=\beta _{0}^{*}+\beta _{1}^{*}x_{i}+\beta _{2}^{*}z_{i}^{*}$\end{document}logitPrYi=1|xi,zi∗=β0∗+β1∗xi+β2∗zi∗, under the null hypothesis \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$H_{0}^{*}$\end{document}H0∗: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\beta _{1}^{*}=\beta _{2}^{*}=0$\end{document}β1∗=β2∗=0, the joint score test statistic TLev is asymptotically chi-squared distributed with two degrees of freedom: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$\begin{array}{@{}rcl@{}} T^{Lev}=\left(\mathbf{U}^{Lev}\right)^{T}\left(\widehat{\mathbf{\Sigma}}^{Lev}\right)^{-1}\mathbf{U}^{Lev} \stackrel{H_{0}^{*}}{\rightarrow} \chi^{2}_{2}, \end{array} $$ \end{document}TLev=ULevTΣ^Lev−1ULev→H0∗χ22, </plain></SENT>
</text></p><p><text><SENT sid="62" pm="."><plain>where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\mathbf {U}^{Lev}=\left (U_{1}, U_{2}^{*}\right)^{T}$\end{document}ULev=U1,U2∗T, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$U_{2}^{*}=\sum _{i=1}^{n}z_{i}^{*}\left (y_{i}-\bar {y}\right)$\end{document}U2∗=∑i=1nzi∗yi−y¯, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$\widehat{\mathbf{\Sigma}}^{Lev}=n\bar{y}\left(1-\bar{y}\right) \left(\begin{array}{cc} \hat{\sigma}_{x}^{2}&amp;\hat{\sigma}_{xz^{*}}\\ \hat{\sigma}_{xz^{*}}&amp;\hat{\sigma}_{z^{*}}^{2} \end{array} \right), $$ \end{document}Σ^Lev=ny¯1−y¯σ^x2σ^xz∗σ^xz∗σ^z∗2, where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\hat {\sigma }_{z^{*}}^{2}$\end{document}σ^z∗2 is the sample variance for \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$z_{i}^{*}$\end{document}zi∗, and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\hat {\sigma }_{xz^{*}}$\end{document}σ^xz∗ is the sample covariance between xi and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$z_{i}^{*}$\end{document}zi∗. </plain></SENT>
<SENT sid="63" pm="."><plain>Note that the proposed improved joint test is different from Levene’s test [10] in that Levene’s test regards \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$z_{i}^{*}$\end{document}zi∗ as random and uses ANOVA, while the proposed improved joint test regards \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$z_{i}^{*}$\end{document}zi∗ as fixed (i.e., non-random) and uses a logistic regression framework. </plain></SENT>
</text></p><p><text><SENT sid="64" pm="."><plain>In the second improved joint score test, we replace the sample means in the TLev by sample medians [11]: 5\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$\begin{array}{@{}rcl@{}} z_{i}^{BF}= \left\{ \begin{array}{ll} |x_{i}-\tilde{x}_{1}|, \text{if } Y_{i}=1,\\ |x_{i}-\tilde{x}_{0}|, \text{if } Y_{i}=0, \end{array} \right. \end{array} $$ \end{document}ziBF=|xi−x~1|,ifYi=1,|xi−x~0|,ifYi=0, </plain></SENT>
</text></p><p><text><SENT sid="65" pm="."><plain>where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\tilde {x}_{1}$\end{document}x~1 and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\tilde {x}_{0}$\end{document}x~0 are the sample medians for cases and controls respectively. </plain></SENT>
<SENT sid="66" pm="."><plain>Under the null hypothesis \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$H_{0}^{BF}: \beta _{0}^{BF}=\beta _{1}^{BF}=0$\end{document}H0BF:β0BF=β1BF=0, the joint score test statistic TBF follows asymptotically the chi-squared distribution with two degrees of freedom: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$\begin{array}{@{}rcl@{}} T^{BF}=\left(\mathbf{U}^{BF}\right)^{T}\left(\widehat{\mathbf{\Sigma}}^{BF}\right)^{-1}\mathbf{U}^{BF}\stackrel{H_{0}^{BF}}{\rightarrow} \chi^{2}_{2}, \end{array} $$ \end{document}TBF=UBFTΣ^BF−1UBF→H0BFχ22, </plain></SENT>
</text></p><p><text><SENT sid="67" pm="."><plain>where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\mathbf {U}^{BF}=\left (U_{1}, U_{2}^{BF}\right)^{T}$\end{document}UBF=U1,U2BFT, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$U_{2}^{BF}=\sum _{i=1}^{n}z_{i}^{BF}\left (y_{i}-\bar {y}\right)$\end{document}U2BF=∑i=1nziBFyi−y¯, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$\widehat{\mathbf{\Sigma}}^{BF}=n\bar{y}\left(1-\bar{y}\right) \left(\begin{array}{cc} \hat{\sigma}_{x}^{2}&amp;\hat{\sigma}_{xz^{BF}}\\ \hat{\sigma}_{xz^{BF}}&amp;\hat{\sigma}_{z^{BF}}^{2} \end{array} \right), $$ \end{document}Σ^BF=ny¯1−y¯σ^x2σ^xzBFσ^xzBFσ^zBF2, where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\hat {\sigma }_{z^{BF}}^{2}$\end{document}σ^zBF2 is the sample variance for \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$z_{i}^{BF}$\end{document}ziBF, and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\hat {\sigma }_{xz^{BF}}$\end{document}σ^xzBF is the sample covariance between xi and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$z_{i}^{BF}$\end{document}ziBF. </plain></SENT>
</text></p><p><text><SENT sid="68" pm="."><plain>In the third improved joint score test, we replace the sample means in the TLev by trimmed sample means [11]: 6\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$\begin{array}{@{}rcl@{}} z_{i}^{TM}= \left\{ \begin{array}{ll} |x_{i}-\check{x}_{1}|, \text{if } Y_{i}=1,\\ |x_{i}-\check{x}_{0}|, \text{if } Y_{i}=0, \end{array} \right. \end{array} $$ \end{document}ziTM=|xi−xˇ1|,ifYi=1,|xi−xˇ0|,ifYi=0, </plain></SENT>
</text></p><p><text><SENT sid="69" pm="."><plain>where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\check {x}_{1}$\end{document}xˇ1 and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\check {x}_{0}$\end{document}xˇ0 are the 25% trimmed sample means for cases and controls respectively. </plain></SENT>
<SENT sid="70" pm="."><plain>The 25% trimmed mean for a sample is the sample mean after trimming 25% lowest values and 25% highest values. </plain></SENT>
</text></p><p><text><SENT sid="71" pm="."><plain>For the logistic regression model \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$logit \left [Pr \left ({\vphantom {z_{i}^{TM}}} Y_{i}=1\right.\right. \left.\left. |x_{i},z_{i}^{TM}\right)\right ] =\beta _{0}^{TM}+\beta _{1}^{TM}x_{i}+\beta _{2}^{TM}z_{i}^{TM}$\end{document}logitPrYi=1|xi,ziTM=β0TM+β1TMxi+β2TMziTM, under the null hypothesis \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$H_{0}^{TM}$\end{document}H0TM: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\beta _{1}^{TM}=\beta _{2}^{TM}=0$\end{document}β1TM=β2TM=0, the joint score test statistic TTM is asymptotically chi-squared distributed with two degrees of freedom: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$\begin{array}{@{}rcl@{}} T^{TM}=\left(\mathbf{U}^{TM}\right)^{T}\left(\widehat{\mathbf{\Sigma}}^{TM}\right)^{-1}\mathbf{U}^{TM} \stackrel{H_{0}^{TM}}{\rightarrow} \chi^{2}_{2}, \end{array} $$ \end{document}TTM=UTMTΣ^TM−1UTM→H0TMχ22, </plain></SENT>
</text></p><p><text><SENT sid="72" pm="."><plain>where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\mathbf {U}^{TM}=\left (U_{1}, U_{2}^{TM}\right)^{T}$\end{document}UTM=U1,U2TMT, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$U_{2}^{TM}=\sum _{i=1}^{n}z_{i}^{TM}\left (y_{i}-\bar {y}\right)$\end{document}U2TM=∑i=1nziTMyi−y¯, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document} $$\widehat{\mathbf{\Sigma}}^{TM}=n\bar{y}\left(1-\bar{y}\right) \left(\begin{array}{cc} \hat{\sigma}_{x}^{2}&amp;\hat{\sigma}_{xz^{TM}}\\ \hat{\sigma}_{xz^{TM}}&amp;\hat{\sigma}_{z^{TM}}^{2} \end{array} \right), $$ \end{document}Σ^TM=ny¯1−y¯σ^x2σ^xzTMσ^xzTMσ^zTM2, where \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\hat {\sigma }_{z^{TM}}^{2}$\end{document}σ^zTM2 is the sample variance for \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$z_{i}^{TM}$\end{document}ziTM, and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$\hat {\sigma }_{xz^{TM}}$\end{document}σ^xzTM is the sample covariance between xi and \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$z_{i}^{TM}$\end{document}ziTM. </plain></SENT>
</text></p></sec></sec></sec></SecTag><SecTag type="RESULTS"><sec id="Sec5" sec-type="results"><title><text><SENT sid="73" pm="."><plain>Results </plain></SENT>
</text></title><sec id="Sec6"><title><text><SENT sid="74" pm="."><plain>Simulation studies </plain></SENT>
</text></title><p><text><SENT sid="75" pm="."><plain>We have conducted comprehensive simulations to compare the performances of the three improved tests with the three existing methods: the joint likelihood ratio test based on the normal distribution (jointLRT) [12, 13], the Kolmogorov-Smirnov test (KS) [14], and Ahn and Wang’s joint score test (AW). </plain></SENT>
<SENT sid="76" pm="."><plain>We have attained the mathematical expression and the exact distribution of jointLRT test statistics under normal distribution [15]. </plain></SENT>
<SENT sid="77" pm="."><plain>Due to computational complexity, we used the asymptotic distribution of jointLRT in our simulation studies. </plain></SENT>
</text></p><p><text><SENT sid="78" pm="."><plain>The simulation studies examined the following four aspects and their impacts on these six tests: (1) various sample sizes, (2) the presence of heterogeneity of means and variances, (3) the violation of the normality assumption, and (4) outliers. </plain></SENT>
<SENT sid="79" pm="."><plain>We considered various sample sizes: (n0,n1) =(100, 100), (n0,n1) =(50, 50), and (n0,n1)=(20, 20). </plain></SENT>
<SENT sid="80" pm="."><plain>Four parametric models were employed to generate the methylation data: the normal distribution, the Beta distribution, the chi-square distribution, and the mixture of two normal distributions. </plain></SENT>
<SENT sid="81" pm="."><plain>To evaluate the impact of outliers, we replaced the DNA methylation level of one randomly picked disease subject by max{x1,max,(Q3+3(Q3−Q1))}, where x1,max denotes the maximum DNA methylation level of the diseased samples, and Q1 and Q3 are the first and third quartiles respectively. </plain></SENT>
</text></p><p><text><SENT sid="82" pm="."><plain>We computed the empirical Type I error rates and the powers of the six tests under different scenarios: (1) Type I error scenario (eqM &amp; eqV): distributions of non-diseased and diseased samples are the same; (2) Power scenario I (diffM &amp; eqV): distributions of non-diseased and diseased samples are different in means only; (3) Power scenario II (eqM &amp; diffV): distributions of non-diseased and diseased samples are different in variances only; and (4) Power scenario III (diffM &amp; diffV): distributions of non-diseased and diseased samples are different in both means and variances. </plain></SENT>
<SENT sid="83" pm="."><plain>We conducted 10,000 simulations to estimate Type I error rates for scenario (1). </plain></SENT>
<SENT sid="84" pm="."><plain>For the remaining 3 scenarios, 5000 simulations are conducted to estimate the power of a test using the corrected cutoff values obtained in scenario (1) so that corrected Type I error rates are approximately equal to the nominal Type I error rates. </plain></SENT>
</text></p><p><text><SENT sid="85" pm="."><plain>Overall, the three improved joint score tests performed better than the other three methods when methylation levels contained outliers and had different variances between diseased and non-diseased samples. </plain></SENT>
<SENT sid="86" pm="."><plain>Besides, iAW.BF is the most robust in terms of power among all the scenarios. </plain></SENT>
<SENT sid="87" pm="."><plain>The KS test had conservative empirical Type I error rates and lowest power in many scenarios. </plain></SENT>
</text></p><p><text><SENT sid="88" pm="."><plain>When methylation levels were generated based on normal distributions without outliers, all tests had the empirical Type I error rates close to the nominal levels, except for KS (Table 1). </plain></SENT>
<SENT sid="89" pm="."><plain>For Power Scenarios I, II and III, three improved joint score tests had similar performances, but slightly lower power for jointLRT and AW. </plain></SENT>
<SENT sid="90" pm="."><plain>When methylation values were from normal distributions with an outlier, the three improved joint score tests can keep empirical Type I error rates well at all nominal levels. </plain></SENT>
<SENT sid="91" pm="."><plain>Whereas the empirical Type I error rates of jointLRT were inflated at all nominal levels, AW and KS had very conservative empirical Type I error rates at all levels (Table 1). </plain></SENT>
<SENT sid="92" pm="."><plain>For Power Scenarios I, II and III, the three improved tests had similar or greater power than AW. </plain></SENT>
<SENT sid="93" pm="."><plain>For Power Scenarios II and III (i.e. different variances), KS had poor estimated power despite the presence or absence of an outlier. </plain></SENT>
<SENT sid="94" pm="."><plain>Similar findings about KS are also observed in other parametric distributions (Tables 2 and 4). Table 1The empirical Type I error rates (× 100) and power (× 100) for the six tests when methylation values were generated from normal distributions without (Outlier=No) or with an outlier (Outlier =Yes). </plain></SENT>
<SENT sid="95" pm="."><plain>The numbers of non-diseased and diseased samples are (100, 100)ScenariosOutlierα(%)jointLRTKSAWiAW.LeviAW.BFiAW.TMeqM&amp;eqVNo55.13.45.15.15.05.1(Type I error)No11.00.51.11.01.01.1No0.50.50.40.60.60.50.6diffM&amp;eqVNo597.395.597.197.197.297.2No190.284.989.489.890.089.7No0.585.375.084.383.183.883.6eqM&amp;diffVNo590.025.187.384.183.883.8No174.36.165.763.562.962.6No0.566.32.455.251.652.052.5diffM&amp;diffVNo583.263.981.079.379.279.3No163.736.859.956.956.856.3No0.553.924.548.845.546.346.2eqM&amp;eqVYes512.23.23.74.84.84.8(Type I error)Yes13.70.50.50.90.91.0Yes0.52.30.40.30.40.40.4diffM&amp;eqVYes595.694.998.498.198.198.1Yes183.086.694.592.392.792.4Yes0.577.576.991.089.490.089.3eqM&amp;diffVYes546.316.754.369.368.868.9Yes120.35.331.543.043.543.2Yes0.515.12.222.836.036.836.1diffM&amp;diffVYes554.658.475.578.478.578.7Yes126.538.256.956.157.257.0Yes0.520.325.847.548.450.449.1 Table 2The empirical Type I error rates (× 100) and power (× 100) of the six tests when methylation values were generated from Beta distributions. </plain></SENT>
<SENT sid="96" pm="."><plain>The numbers of non-diseased and diseased samples are (100, 100)ScenariosOutlierα(%)jointLRTKSAWiAW.LeviAW.BFiAW.TMeqM&amp;eqVNo55.73.55.45.45.45.5(Type I error)No11.50.51.01.11.21.1No0.50.80.30.50.50.50.5diffM&amp;eqVNo596.894.797.597.297.497.4No188.486.791.790.591.090.9No0.583.177.587.886.687.987.4eqM&amp;diffVNo588.118.986.883.182.783.0No168.66.265.862.260.661.3No0.560.42.555.653.552.653.2diffM&amp;diffVNo583.564.588.684.985.885.9No158.142.870.463.064.564.8No0.548.930.260.654.657.656.8eqM&amp;eqVYes511.03.63.854.94.9(Type I error)Yes13.30.60.71.01.01.0Yes0.51.80.30.30.50.50.5diffM&amp;eqVYes597.695.998.898.698.898.7Yes189.287.794.893.494.093.7Yes0.582.679.691.689.389.989.8eqM&amp;diffVYes531.915.724.961.259.860.6Yes111.55.16.733.031.332.1Yes0.56.62.04.023.221.322.0diffM&amp;diffVYes526.459.936.652.653.453.6Yes18.438.315.424.925.725.5Yes0.54.526.010.616.517.217.2 </plain></SENT>
</text></p><p><text><SENT sid="97" pm="."><plain>Similar findings were also observed for the Beta distribution setting (Table 2). </plain></SENT>
<SENT sid="98" pm="."><plain>When the Beta distributions of two groups were different in variances (Power Scenarios II and III) and contained outliers, the three improved tests had significantly greater power than AW. </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>When methylation values were generated from a two-component normal mixture distribution without (Table 3), both iAW.BF and AW had appropriate empirical Type I error rates. </plain></SENT>
<SENT sid="100" pm="."><plain>However, iAW.Lev and iAW.TM had significantly inflated empirical Type I error rates. </plain></SENT>
<SENT sid="101" pm="."><plain>Additionally, jointLRT and KS had conservative empirical Type I error rates. </plain></SENT>
<SENT sid="102" pm="."><plain>Under all Power Scenarios, iAW.BF had greater power than AW and jointLRT. </plain></SENT>
<SENT sid="103" pm="."><plain>When methylation values were from two-component normal mixture distributions with an outlier, iAW.BF had appropriate simulated Type I error rates at each level. </plain></SENT>
<SENT sid="104" pm="."><plain>Although iAW.Lev and iAW.TM had increased empirical Type I error rates, they are much smaller than those rates of jointLRT. </plain></SENT>
<SENT sid="105" pm="."><plain>Whereas KS and AW had conservative empirical Type I error rates. </plain></SENT>
<SENT sid="106" pm="."><plain>All of the three improved tests had significantly greater power than AW under Power scenarios II (i.e. different variances only) and III (i.e. different means and different variances). Table 3The empirical Type I error rates (× 100) and power (× 100) for the six tests when methylation values generated from mixtures of two normal distributions. </plain></SENT>
<SENT sid="107" pm="."><plain>The numbers of non-diseased and diseased samples are (100, 100)ScenariosOutlierα(%)jointLRTKSAWiAW.LeviAW.BFiAW.TMeqM&amp;eqVNo52.43.84.99.45.412.3(Type I error)No10.40.70.83.21.34.5No0.50.20.40.42.00.82.8diffM&amp;eqVNo516.658.474.956.287.053.6No14.030.855.126.665.825.5No0.52.325.545.117.853.919.6eqM&amp;diffVNo534.598.155.188.857.869.9No110.581.136.171.632.447.7No0.56.472.728.962.523.640.5diffM&amp;diffVNo537.798.761.192.068.376.4No112.085.241.577.242.654.3No0.57.878.134.068.332.246.7eqM&amp;eqVYes525.03.92.86.54.88.1(Type I error)Yes16.80.70.41.41.02.1Yes0.53.70.40.20.70.61.3diffM&amp;eqVYes54.259.416.321.578.134.9Yes11.132.15.15.255.79.8Yes0.50.526.53.33.544.75.2eqM&amp;diffVYes50.697.414.480.249.663.3Yes10.179.55.159.827.439.4Yes0.50.071.23.554.119.731.5diffM&amp;diffVYes51.098.119.584.661.071.1Yes10.283.67.565.737.547.0Yes0.50.176.85.660.127.938.1 Table 4The empirical Type I error rates (× 100) and power (× 100) for the six tests when methylation values generated from chi-squared distributions. </plain></SENT>
<SENT sid="108" pm="."><plain>The numbers of non-diseased and diseased samples are (100, 100)ScenariosOutlierα(%)jointLRTKSAWiAW.LeviAW.BFiAW.TMeqM&amp;eqVNo513.84.25.06.35.35.2(Type I errror)No16.30.70.91.51.31.2No0.54.40.40.40.80.50.5diffM&amp;eqVNo590.299.799.899.699.999.9No153.897.199.097.199.499.4No0.540.995.998.194.999.299.0eqM&amp;diffVNo518.610.229.229.635.434.6No15.82.110.311.414.715.0No0.53.91.36.97.011.110.4diffM&amp;diffVNo518.442.259.954.970.669.0No13.717.935.727.545.543.8No0.52.113.927.918.938.935.6eqM&amp;eqVYes520.14.04.86.75.55.3(Type I error)Yes110.30.70.71.71.11.1Yes0.57.80.50.20.80.50.5diffM&amp;eqVYes567.999.599.999.499.999.9Yes123.796.599.196.499.499.3Yes0.512.995.098.794.099.098.8eqM&amp;diffVYes527.59.534.039.741.041.5Yes19.91.811.916.619.319.0Yes0.56.11.17.311.214.013.7diffM&amp;diffVYes521.939.865.260.473.272.1Yes16.316.339.931.749.747.7Yes0.53.412.232.523.941.839.7 </plain></SENT>
</text></p><p><text><SENT sid="109" pm="."><plain>When methylation values were generated from a chi-squared distribution without (Table 4), iAW.BF, iAW.TM and AW kept empirical Type I error rates well, though iAW.Lev presented increased empirical Type I error rates. </plain></SENT>
<SENT sid="110" pm="."><plain>While jointLRT had inflated empirical Type I error rates, and KS has rather conservative empirical Type I error rates. </plain></SENT>
<SENT sid="111" pm="."><plain>For Power scenarios II and III (i.e. different variances), iAW.BF and iAW.TM had significantly greater power than AW. </plain></SENT>
<SENT sid="112" pm="."><plain>Besides, iAW.Lev had similar power to AW for three power scenarios. </plain></SENT>
<SENT sid="113" pm="."><plain>When methylation values were generated from chi-squared distribution with an outlier, the performances of all tests are similar except that AW had conservative empirical Type I error rates. </plain></SENT>
</text></p><p><text><SENT sid="114" pm="."><plain>From the results of the four tables, we found that iAW.BF could control empirical Type I error rates well and have similar or greater power than AW under all scenarios including the existence of outliers, skewed distributions and mixtures of two normal distributions. </plain></SENT>
<SENT sid="115" pm="."><plain>Except for the scenarios of mixtures of two normal distributions, iAW.Lev and iAW.TM can maintain empirical Type I error rates at proper levels and had similar or greater power than AW. </plain></SENT>
<SENT sid="116" pm="."><plain>In comparison, AW can keep appropriate empirical Type I error rates for any parametric distributions as designed without outliers. </plain></SENT>
<SENT sid="117" pm="."><plain>But when the methylation values were generated from a distribution with an outlier, AW tended to have conservative empirical Type I error rates and smaller estimated power. </plain></SENT>
<SENT sid="118" pm="."><plain>The jointLRT, on the other hand, only performed best for methylation values generated from normal distributions without outliers. </plain></SENT>
<SENT sid="119" pm="."><plain>KS can keep conservative empirical Type I error rates under all scenarios, and it had poor estimated power in many scenarios. </plain></SENT>
</text></p><p><text><SENT sid="120" pm="."><plain>Simulation studies were also conducted when sample size was moderate (50, 50) or small (20, 20). </plain></SENT>
<SENT sid="121" pm="."><plain>The results are provided in Additional file 1: Tables S2-S9). </plain></SENT>
<SENT sid="122" pm="."><plain>We observed that empirical Type I error rates increased and power decreased when sample size decreased from 100 to 50 subjects per group. </plain></SENT>
<SENT sid="123" pm="."><plain>Furthermore, the three improved joint score tests still performed significantly better than AW under moderate or small sample size. </plain></SENT>
</text></p></sec><sec id="Sec7"><title><text><SENT sid="124" pm="."><plain>Real data analyses </plain></SENT>
</text></title><p><text><SENT sid="125" pm="."><plain>We applied all six statistical tests to three publicly available DNA methylation data sets (GSE37020 [16], GSE20080 [17] and GSE107080 [18]) from Gene Expression Omnibus (GEO)(<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo">www.ncbi.nlm.nih.gov/geo</ext-link>). </plain></SENT>
</text></p><p><text><SENT sid="126" pm="."><plain>GSE37020 and GSE20080 used Illumina HumanMethylation27 (HM27k) platform to produce DNA methylation profiles for 27,578 CpG sites. </plain></SENT>
<SENT sid="127" pm="."><plain>Both data sets measured cervical smear samples collected from normal histology (regarded as normal samples) and changed tissues with cervical intraepithelial neoplasia of grade 2 or higher (CIN2+) (CIN2+ samples). </plain></SENT>
<SENT sid="128" pm="."><plain>GSE37020 contains 24 normal samples and 24 CIN2+ samples, while GSE20080 contains 30 normal samples and 18 CIN2+ samples. </plain></SENT>
<SENT sid="129" pm="."><plain>GSE107080 contained DNA methylation profiles of about 850K sites measured from whole blood samples using Illumina Infinium MethylationEPIC (EPIC) platform. </plain></SENT>
<SENT sid="130" pm="."><plain>GSE107080 included 100 individuals with illicit drug injection and hepatitis C type virus (IDU+/HCV+) and 305 individuals without illicit drug injection and hepatitis C type virus (IDU-/HCV-). </plain></SENT>
<SENT sid="131" pm="."><plain>All the individuals are recruited from a well-established longitudinal cohort, Veteran Aging Cohort Study. </plain></SENT>
</text></p><p><text><SENT sid="132" pm="."><plain>For GSE37020 and GSE20080, we excluded CpG sites residing near SNPs or with missing values. </plain></SENT>
<SENT sid="133" pm="."><plain>Quantile plots and principal component analysis did not show obvious and suspicious patterns (for details please refer to [4]). </plain></SENT>
<SENT sid="134" pm="."><plain>We then obtained residuals of samples after regressing out the effect of age from DNA methylation levels. </plain></SENT>
<SENT sid="135" pm="."><plain>We re-did the principal component analysis on the adjusted data and did not find any obvious patterns (see Additional file 1: Figure S2). </plain></SENT>
<SENT sid="136" pm="."><plain>After data quality control and preprocessing (for details please refer to [4]), there were 22,859 CpG sites appearing in both cleaned data sets. </plain></SENT>
</text></p><p><text><SENT sid="137" pm="."><plain>We used cleaned GSE37020 as the discovery set and cleaned GSE20080 as the validation set to detect CpG sites differentially methylated (DM) or differentially variable (DV) between CIN2+ samples and normal samples. </plain></SENT>
<SENT sid="138" pm="."><plain>For a given CpG site in a given data set, we applied each of the six joint tests to test for equalities of both means and variances. </plain></SENT>
<SENT sid="139" pm="."><plain>For a given joint test, we claimed a CpG site in the analysis of GSE37020 as significant methylation candidate (different in means or variances) if the false discovery rate (FDR) [19] adjusted p-value for the CpG site is less than 0.05. </plain></SENT>
<SENT sid="140" pm="."><plain>The function p.adjust in the statistical software R was used to calculate FDR-adjusted p-value. </plain></SENT>
<SENT sid="141" pm="."><plain>For a significant site in the analysis of GSE37020, if the corresponding un-adjusted p-value in the analysis of GSE20080 is less than 0.05 and the difference directions of means and variances are consistent between the two data sets, then we claim that the significance in the analysis of GSE37020 is truly validated in the analysis of GSE20080. </plain></SENT>
<SENT sid="142" pm="."><plain>We use the differences of medians and mean absolute deviations between cases and controls to evaluate the directions. </plain></SENT>
</text></p><p><text><SENT sid="143" pm="."><plain>For HM27k data set GSE37020, the numbers of significant CpG sites (i.e., CpG sites with FDR-adjusted p-value &lt; 0.05) obtained by the 6 joint tests are 4556 (jointLRT), 1288 (KS), 1850 (AW), 2041 (iAW.Lev), 1843 (iAW.BF) and 1838 (iAW.TM). </plain></SENT>
<SENT sid="144" pm="."><plain>And the truly validated CpG sites are 1705 (jointLRT), 47 (KS), 220 (AW), 666 (iAW.Lev), 296 (iAW.BF) and 342 (iAW.TM). </plain></SENT>
</text></p><p><text><SENT sid="145" pm="."><plain>Table 5 presents the numbers/proportions of truly and falsely validated significant CpG sites. </plain></SENT>
<SENT sid="146" pm="."><plain>The three improved joint score tests have higher true validation ratios than joint LRT, KS test, and AW test. </plain></SENT>
<SENT sid="147" pm="."><plain>Among all the tests, iAW.Lev had the highest true validation rate (89.2%) and lowest false validation rate (10.8%), followed by iAW.TM and iAW.BF. </plain></SENT>
<SENT sid="148" pm="."><plain>And we also applied the 6 joint tests on the adjusted data sets, the performances of them are similar (see Additional file 1: Table S1). Table 5The performances of 6 joint tests based on HM27k data GSE37020 and GSE20080TestnSignValidationnTVpTV(%)nFVpFV(%)JointLRT45562213170577.050823.0KS1288604778.31321.7AW185026222084.04216.0iAW.Lev204174766689.28110.8iAW.BF184333929687.34312.7iAW.TM183838734288.44511.6nSig: the number of significant CpG sites detected in GSE37020 based on FDR adjusted p-value &lt; 0.05;nValidation: the number of validated CpG sites in GSE20080 based on unadjusted p-value &lt; 0.05;nTV: the number of truly validated CpG sites with the same difference directions in means and variances between the two groups;pTV: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$=\frac {nTV}{nValidation}$\end{document}=nTVnValidation, the proportion of significant CpG sites detected in GSE37020 and truly validated in GSE20080;nFV: the number of falsely validated CpG sites in GSE20080 with inconsistent difference direction in means or variances between the two groups;pFV: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$=\frac {nFV}{nValidation}$\end{document}=nFVnValidation, the proportion of significant CpG sites detected in GSE37020 but falsely validated in GSE20080 </plain></SENT>
</text></p><p><text><SENT sid="149" pm="."><plain>Figure 1 showed the parallel boxplots of DNA methylation levels versus case-control status for the top CpG site (i.e. having the smallest p-value among those truly validated CpG sites for testing homogeneity of means and variances simultaneously) obtained by each of the 6 joint tests. </plain></SENT>
<SENT sid="150" pm="."><plain>All these top CpG sites were validated in GSE20080. </plain></SENT>
<SENT sid="151" pm="."><plain>It has been found that the high incidence of cervical lesions is associated to the genes ST6GALNAC3, CRB1 and RGS7, where cg26363196 (jointLRT), cg00321478 (AW) and cg21303386 (iAW.Lev) might reside [20, 21]. </plain></SENT>
<SENT sid="152" pm="."><plain>Furthermore, the gene PRRG2, where cg2196766 (KS) might reside, is involved in signal transduction pathway, which might be a novel biomarker for CIN2+ diagnosis [22]. </plain></SENT>
<SENT sid="153" pm="."><plain>And the gene FPRL2, where cg06784466 (iAW.BF, iAW.TM) might reside, are related to innate immunity and host defense mechanisms [23]. Fig. 1Paired parallel boxplots of DNA methylation levels (y axis) versus case-control status (x axis) for the 5 unique top CpG sites acquired by the 6 joint tests based on HM27k data sets. </plain></SENT>
<SENT sid="154" pm="."><plain>The dots indicate subjects.1A and 1B are for cg26363196 (jointLRT). </plain></SENT>
<SENT sid="155" pm="."><plain>2A and 2B are for cg2196766 (KS). </plain></SENT>
<SENT sid="156" pm="."><plain>3A and 3B are for cg00321478 (AW). </plain></SENT>
<SENT sid="157" pm="."><plain>4A and 4B are for cg21303386 (iAW.Lev). </plain></SENT>
<SENT sid="158" pm="."><plain>5A and 5B are for cg06784466 (iAW.BF, iAW.TM). </plain></SENT>
<SENT sid="159" pm="."><plain>1A,2A,3A,4A,5A are based on GSE37020. </plain></SENT>
<SENT sid="160" pm="."><plain>1B,2B,3B,4B,5B are based on GSE20080 </plain></SENT>
</text></p><p><text><SENT sid="161" pm="."><plain>For GSE107080, we downloaded the processed data set from GEO database [18]. </plain></SENT>
<SENT sid="162" pm="."><plain>We first removed the CpG sites with at least one missing value or with probe name using “ch” as the prefix. </plain></SENT>
<SENT sid="163" pm="."><plain>Secondly, CpG sites with detection p-values larger than or equal to 10−12 are discarded. </plain></SENT>
<SENT sid="164" pm="."><plain>There are 378,808 CpG sites in the cleaned data set. </plain></SENT>
<SENT sid="165" pm="."><plain>We drew the plot of quantiles across arrays and did a principal component analysis for the cleaned GSE107080 data set. </plain></SENT>
<SENT sid="166" pm="."><plain>The results did not show any obvious patterns (see Additional file 1: Figure S3). </plain></SENT>
<SENT sid="167" pm="."><plain>Additionally, we regressed out the effects of age and cell type compositions and obtained the residuals. </plain></SENT>
<SENT sid="168" pm="."><plain>There are 378,808 CpG sites and 309 samples (cases: 95 and controls: 295) left in the data set after the adjustment. </plain></SENT>
<SENT sid="169" pm="."><plain>Results from the principal component analysis on the adjusted data did not show any obvious patterns (see Additional file 1: Figure S4). </plain></SENT>
</text></p><p><text><SENT sid="170" pm="."><plain>For the EPIC data set GSE107080, the samples were randomly split into two sets with approximately equal size (due to odd numbers of cases and controls) as the training set and the validation set. </plain></SENT>
<SENT sid="171" pm="."><plain>The training set contained 148 controls (IDU-/HCV-) and 48 cases (IDU+/HCV+), and the validation set contained 147 controls and 47 cases. </plain></SENT>
<SENT sid="172" pm="."><plain>We use the similar method as above to determine if the significance of a CpG site is truly validated. </plain></SENT>
</text></p><p><text><SENT sid="173" pm="."><plain>For GSE107080, the numbers of significant CpG sites (i.e., CpG sites with FDR-adjusted p-value &lt; 0.05) obtained by the 6 joint tests in the training set are 51,994 (jointLRT), 10 (KS), 12 (AW), 709 (iAW.Lev), 22 (iAW.BF) and 22 (iAW.TM). </plain></SENT>
<SENT sid="174" pm="."><plain>And the corresponding numbers of validated CpG sites in the validation set (i.e., CpG sites with unadjusted p-value &lt; 0.05) are 19,806 (jointLRT), 3 (KS), 5 (AW), 201 (iAW.Lev), 7 (iAW.BF) and 9 (iAW.TM). </plain></SENT>
<SENT sid="175" pm="."><plain>After checking the difference directions, the truly validated CpG sites are 5652 (jointLRT), 1 (KS), 2 (AW), 89 (iAW.Lev), 4 (iAW.BF) and 5 (iAW.TM). </plain></SENT>
</text></p><p><text><SENT sid="176" pm="."><plain>Table 6 presents the numbers/proportions of truly and falsely validated significant CpG sites based on GSE107080. </plain></SENT>
<SENT sid="177" pm="."><plain>The three improved tests have higher true validation ratios than joint LRT, KS and AW tests. </plain></SENT>
<SENT sid="178" pm="."><plain>Among the three improved tests, iAW.BF and iAW.TM have more than ten percent higher proportion of true validation than AW. Table 6The performances of 6 joint tests based on EPIC data GSE107080TestnSignValidationnTVpTV(%)nFVpFV(%)JointLRT5199419806565228.51415471.5KS103133.3266.7AW125240.0360.0iAW.Lev7092018944.311255.7iAW.BF227457.1342.9iAW.TM229555.6444.4nSig: the number of significant CpG sites detected in the training set of GSE107080 based on FDR adjusted p-value &lt; 0.05;nValidation: the number of validated CpG sites in the validation set of GSE107080 based on unadjusted p-value &lt; 0.05;nTV: the number of truly validated CpG sites with the same difference directions in means and variances between the two groups;pTV: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$=\frac {nTV}{nValidation}$\end{document}=nTVnValidation, the proportion of significant CpG sites detected in the training set and truly validated in the validation set;nFV: the number of falsely validated CpG sites in validation set with inconsistent difference direction in means or variances between the two groups;pFV: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$=\frac {nFV}{nValidation}$\end{document}=nFVnValidation, the proportion of significant CpG sites detected in the training set but falsely validated in the validation set </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="Sec8" sec-type="discussion"><title><text><SENT sid="179" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="180" pm="."><plain>The three improved joint score tests are derived from generalized linear model framework as AW. </plain></SENT>
<SENT sid="181" pm="."><plain>Thus they maintain the strengths of AW in terms of efficiency. </plain></SENT>
<SENT sid="182" pm="."><plain>Furthermore, the three improved tests use absolute deviation instead of squared deviation used by AW to enhance the robustness. </plain></SENT>
<SENT sid="183" pm="."><plain>For skewed methylation distributions or distributions with outliers, squared deviation used by AW can be enormously affected by extreme values and leads to erroneous results. </plain></SENT>
<SENT sid="184" pm="."><plain>Thus AW tends to have conservative empirical Type I error rates and smaller power in some scenarios. </plain></SENT>
<SENT sid="185" pm="."><plain>Our proposed methods rectify this problem and can maintain good power even if the distribution is skewed or contains one or more outliers. </plain></SENT>
<SENT sid="186" pm="."><plain>Besides, when compared to squared deviation, absolute deviation retains the same magnitude of the original measurement scales and consequently more interpretable. </plain></SENT>
<SENT sid="187" pm="."><plain>The iAW.Lev tends to have inflated empirical Type I error rates under skewed and mixture distributions. </plain></SENT>
<SENT sid="188" pm="."><plain>In comparison, iAW.BF and iAW.TM employ median and trimmed mean as central tendency respectively to calculate absolute deviation. </plain></SENT>
<SENT sid="189" pm="."><plain>Both of them are robust and can minimize the impact of outliers and skewed distributions in evaluating the overall dispersion of the sample data. </plain></SENT>
</text></p><p><text><SENT sid="190" pm="."><plain>The performance of the jointLRT was highly dependent on the validity of normality assumptions. </plain></SENT>
<SENT sid="191" pm="."><plain>However, the empirical distribution of methylation data often demonstrates skewness and presence of outlying observations. </plain></SENT>
<SENT sid="192" pm="."><plain>The KS test was inclined to have conservative empirical Type I error rates and lowest power under many scenarios. </plain></SENT>
<SENT sid="193" pm="."><plain>Therefore it might not be suitable for DNA methylation analysis as expected. </plain></SENT>
</text></p><p><text><SENT sid="194" pm="."><plain>We would like to address one limitation of our simulation studies. </plain></SENT>
<SENT sid="195" pm="."><plain>Since the analytical form of the underlying probability distribution of methylation data is rarely known, we have applied various settings in an attempt to mimic the reality. </plain></SENT>
<SENT sid="196" pm="."><plain>We also tried to evaluate our methods in four different aspects. </plain></SENT>
<SENT sid="197" pm="."><plain>However, our simulation study might not cover all cases that one might encounter in reality. </plain></SENT>
<SENT sid="198" pm="."><plain>Nevertheless, the results from real data analyses provide strong evidence to support the thesis that our proposed tests are in general more robust in comparison with the AW test. </plain></SENT>
</text></p><p><text><SENT sid="199" pm="."><plain>Another remark is that the AW test and our improved tests are motivated and connected to the logistic regression. </plain></SENT>
<SENT sid="200" pm="."><plain>Potentially, these tests could be applied for prediction of disease. </plain></SENT>
<SENT sid="201" pm="."><plain>The difference of performances of our three proposed tests could be disease-related. </plain></SENT>
<SENT sid="202" pm="."><plain>In other words, one test might be more suitable for one specific type of disease. </plain></SENT>
</text></p><p><text><SENT sid="203" pm="."><plain>We would also like to make some remarks about the important issue of striking a delicate balance between controlling the false positive rate and increasing testing power. </plain></SENT>
<SENT sid="204" pm="."><plain>In genomic data analysis, controlling false positive is an important issue. </plain></SENT>
<SENT sid="205" pm="."><plain>This is why the adjustment of p-values is required to control for multiple testing that could result in highly inflated type I error rates. </plain></SENT>
<SENT sid="206" pm="."><plain>However, when sample size is small (e.g., in pilot studies), we usually have to make some assumptions in order to carry out statistical inference. </plain></SENT>
<SENT sid="207" pm="."><plain>In this case, we can make the normality assumption and apply an F-test to detect differentially variable CpG sites. </plain></SENT>
</text></p><p><text><SENT sid="208" pm="."><plain>Finally, we would like to remark that we can further validate the differentially methylated/variable (DM/DV) CpG sites, which were identified in our real data analysis, by technical validation. </plain></SENT>
<SENT sid="209" pm="."><plain>In the technical validation, we can use pyrosequencing technology to measure more accurately the DNA methylation levels of the identified CpG sites for a subset of cases and controls. </plain></SENT>
<SENT sid="210" pm="."><plain>If one specific CpG site is detected as DM/DV based on the pyrosequenced data, then we gain more evidence that this CpG site is DM/DV. </plain></SENT>
<SENT sid="211" pm="."><plain>Pathway enrichment analysis could also provide further evidence that the identified CpG sites are relevant to the disease of interest. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec id="Sec9" sec-type="conclusion"><title><text><SENT sid="212" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="213" pm="."><plain>Results from simulation studies and real data analyses have demonstrated that the three proposed joint score tests performed better than the existing methods (AW, jointLRT, and KS) for testing equal means and variances simultaneously when methylation levels contained outliers or had different variances between diseased and non-diseased samples. </plain></SENT>
</text></p><p><text><SENT sid="214" pm="."><plain>In general, iAW.BF was the most robust method in terms of power among all the scenarios considered in our simulation study. </plain></SENT>
<SENT sid="215" pm="."><plain>It also has significantly better performance when compared with the AW test. </plain></SENT>
<SENT sid="216" pm="."><plain>For the cases of mixtures of two normal distributions, iAW.Lev and iAW.TM performed similarly to or better than AW. </plain></SENT>
<SENT sid="217" pm="."><plain>In addition, the proposed tests can be easily applied to very large methylation data sets, eg. data sets from the platforms HM27k and EPIC. </plain></SENT>
</text></p></sec></SecTag><sec sec-type="supplementary-material"><title><text><SENT sid="218" pm="."><plain>Additional file </plain></SENT>
</text></title><sec id="Sec10"><p><text><SENT sid="219" pm="."><plain>Additional file 1Supplementary Materials to: Robust Joint Score Tests in the Application of DNA Methylation Data Analysis. </plain></SENT>
<SENT sid="220" pm="."><plain>This file contains: A. </plain></SENT>
<SENT sid="221" pm="."><plain>Derivation of the asymptotic distribution of the AW test statistic; B. </plain></SENT>
<SENT sid="222" pm="."><plain>Quality control and data preprocessing for three real data sets; C. </plain></SENT>
<SENT sid="223" pm="."><plain>Additional simulation results. </plain></SENT>
<SENT sid="224" pm="."><plain>(PDF 365 kb) </plain></SENT>
</text></p></sec></sec></body><back><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list><def-item><term>AW</term><def><p>Ahn and Wang’s joint score test</p></def></def-item><def-item><term>CpG</term><def><p>a type of DNA methylation mark</p></def></def-item><def-item><term>CIN2+</term><def><p>cervical intraepithelial neoplasia of grade 2 or higher</p></def></def-item><def-item><term>DM</term><def><p>differently methylated</p></def></def-item><def-item><term>DV</term><def><p>differently variable</p></def></def-item><def-item><term>diffM</term><def><p>Different means</p></def></def-item><def-item><term>diffV</term><def><p>Different variances</p></def></def-item><def-item><term>EPIC</term><def><p>Illumina Infinium MethylationEPIC</p></def></def-item><def-item><term>eqM</term><def><p>Equal means</p></def></def-item><def-item><term>eqV</term><def><p>Equal variances</p></def></def-item><def-item><term>GEO</term><def><p>Gene Expression Omnibus</p></def></def-item><def-item><term>HCV</term><def><p>hepatitis C type virus</p></def></def-item><def-item><term>HM27k</term><def><p>Illumina HumanMethylation27</p></def></def-item><def-item><term>HM450k</term><def><p>Illumina HumanMethylation450</p></def></def-item><def-item><term>iAW.Lev</term><def><p>improved AW joint score test based on absolute deviation from mean</p></def></def-item><def-item><term>iAW.BF</term><def><p>improved AW joint score test based on absolute deviation from median</p></def></def-item><def-item><term>iAW.TM</term><def><p>improved AW joint score test based on absolute deviation from trimmed mean</p></def></def-item><def-item><term>IDU</term><def><p>illicit drug injection</p></def></def-item><def-item><term>jointLRT</term><def><p>Joint likelihood ratio test</p></def></def-item><def-item><term>KS</term><def><p>Kolmogorov-Smirnov test</p></def></def-item><def-item><term>SNP</term><def><p>single nucleotide polymorphism</p></def></def-item></def-list></glossary></SecTag><fn-group><fn><p><text><SENT sid="225" pm="."><plain>Electronic supplementary material </plain></SENT>
</text></p><p><text><SENT sid="226" pm="."><plain>The online version of this article (10.1186/s12859-018-2185-3) contains supplementary material, which is available to authorized users. </plain></SENT>
</text></p></fn></fn-group><SecTag type="ACK_FUND"><ack><title>Acknowledgements</title><p><text4fund><text><SENT sid="227" pm="."><plain>The authors would like to thank the Editor, an AE, and two referees for their valuable suggestions and comments. </plain></SENT>
</text></text4fund></p><sec id="d29e7434"><title>Funding</title><p><text4fund><text><SENT sid="228" pm="."><plain>This work has been supported by the NSERC Discovery Grants, which played no roles in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. </plain></SENT>
</text></text4fund></p></sec><sec id="d29e7439"><title>Availability of data and materials</title><p><text4fund><text><SENT sid="229" pm="."><plain>The real DNA methylation data sets (GSE37020 [16], GSE20080 [1], and GSE107080 [18]) can be downloaded from Gene Expression Omnibus (GEO). </plain></SENT>
<SENT sid="230" pm="."><plain>The URLs are: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37020">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37020</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20080">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20080</ext-link>, and <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107080">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107080</ext-link>. </plain></SENT>
</text></text4fund></p><p><text4fund><text><SENT sid="231" pm="."><plain>The R package diffMeanVar is publicly available through CRAN (<ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=diffMeanVar">https://CRAN.R-project.org/package=diffMeanVar</ext-link>). </plain></SENT>
</text></text4fund></p></sec></ack></SecTag><SecTag type="SUPPL"><notes notes-type="author-contribution"><title>Authors’ contributions</title><p>XL: data analysis, method development, and manuscript writing; YF: Idea initiation, method development, and manuscript writing; XW: Idea initiation, method development, and manuscript writing; WQ: Idea initiation, method development, and manuscript writing. All authors read and approved the final version of the manuscript.</p></notes></SecTag><notes notes-type="COI-statement"><sec id="d29e7485"><title>Ethics approval and consent to participate</title><p>Not applicable.</p></sec><sec id="d29e7490"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="d29e7495"><title>Publisher’s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><SecTag type="REF"><ref-list id="Bib1"><title>References</title><ref id="CR1"><text><SENT sid="232" pm="."><plain>1TeschendorffAEJonesAFieglHSargentAZhuangJJKitchenerHCWidschwendterMEpigenetic variability in cells of normal cytology is associated with the risk of future morphological transformationGenome Med2012432410.1186/gm323<?supplied-pmid 22453031?>22453031 </plain></SENT>
</text></ref><ref id="CR2"><text><SENT sid="233" pm="."><plain>2PhipsonBOshlackADiffVar: a new method for detecting differential variability with application to methylation in cancer and agingGenome Biol20141546510.1186/s13059-014-0465-4<?supplied-pmid 25245051?>25245051 </plain></SENT>
</text></ref><ref id="CR3"><text><SENT sid="234" pm="."><plain>3WahlSFenskeNZeilingerSSuhreKGiegerCWaldenbergerMGrallertHSchmidMOn the potential of models for location and scale for genome-wide dna methylation dataBMC Bioinformatics201415123210.1186/1471-2105-15-232<?supplied-pmid 24994026?>24994026 </plain></SENT>
</text></ref><ref id="CR4"><text><SENT sid="235" pm="."><plain>4LiXQiuWMorrowJDeMeoDLWeissSTFuYWangXA comparative study of tests for homogeneity of variances with application to dna methylation dataPloS ONE201510120145295 </plain></SENT>
</text></ref><ref id="CR5"><text><SENT sid="236" pm="."><plain>5TeschendorffAEJonesAWidschwendterMStochastic epigenetic outliers can define field defects in cancerBMC Bioinformatics2016171110.1186/s12859-016-1056-z26817711 </plain></SENT>
</text></ref><ref id="CR6"><text><SENT sid="237" pm="."><plain>6QiuWLiXMorrowJDeMeoDWeissSWangXFuYNew score tests for equality of variances in the application of dna methylation data analysis[version 2]Insights Genet Genomics2017132 </plain></SENT>
</text></ref><ref id="CR7"><text><SENT sid="238" pm="."><plain>7ConoverWJJohnsonMEJohnsonMMA comparative study of tests for homogeneity of variances, with applications to the outer continental shelf bidding dataTechnometrics19812343516110.1080/00401706.1981.10487680 </plain></SENT>
</text></ref><ref id="CR8"><text><SENT sid="239" pm="."><plain>8Ahn S, Wang T. </plain></SENT>
<SENT sid="240" pm="."><plain>A powerful statistical method for indentifying differentially methylated markers in complex diseases. </plain></SENT>
<SENT sid="241" pm="."><plain>Pac Symp Biocomput. </plain></SENT>
<SENT sid="242" pm="."><plain>2013;:69–79. </plain></SENT>
</text></ref><ref id="CR9"><text><SENT sid="243" pm="."><plain>9Dobson AJ. </plain></SENT>
<SENT sid="244" pm="."><plain>An Introduction to Generalized Linear Models: Chapman and Hall; 1990. </plain></SENT>
</text></ref><ref id="CR10"><text><SENT sid="245" pm="."><plain>10Levene H. </plain></SENT>
<SENT sid="246" pm="."><plain>Robust tests for equality of variances1. </plain></SENT>
<SENT sid="247" pm="."><plain>Contributions to probability and statistics: Essays in honor of Harold Hotelling. </plain></SENT>
<SENT sid="248" pm="."><plain>1960; 2:278–92. </plain></SENT>
</text></ref><ref id="CR11"><text><SENT sid="249" pm="."><plain>11Brown MB, Forsythe AB. </plain></SENT>
<SENT sid="250" pm="."><plain>Robust Tests for Equality of Variances. </plain></SENT>
<SENT sid="251" pm="."><plain>J Am Stat Assoc. </plain></SENT>
<SENT sid="252" pm="."><plain>1974; 69(May 2015):364–7. </plain></SENT>
<SENT sid="253" pm="."><plain>10.2307/2285659. </plain></SENT>
</text></ref><ref id="CR12"><text><SENT sid="254" pm="."><plain>12PearsonESNeymanJOn the problem of two samples1930BordeauxImprimerie de l’Université </plain></SENT>
</text></ref><ref id="CR13"><text><SENT sid="255" pm="."><plain>13WilksSSThe large-sample distribution of the likelihood ratio for testing composite hypothesesAnn Math Stat193891606210.1214/aoms/1177732360 </plain></SENT>
</text></ref><ref id="CR14"><text><SENT sid="256" pm="."><plain>14ConoverJ. </plain></SENT>
<SENT sid="257" pm="."><plain>W.Practical nonparametric statistics1971New YorkJohn Wiley &amp; Sons </plain></SENT>
</text></ref><ref id="CR15"><text><SENT sid="258" pm="."><plain>15ZhangLXuXChenGThe exact likelihood ratio test for equality of two normal populationsAm Stat2012663180410.1080/00031305.2012.707083 </plain></SENT>
</text></ref><ref id="CR16"><text><SENT sid="259" pm="."><plain>16TeschendorffAEWidschwendterMDifferential variability improves the identification of cancer risk markers in dna methylation studies profiling precursor cancer lesionsBioinformatics2012281114879410.1093/bioinformatics/bts170<?supplied-pmid 22492641?>22492641 </plain></SENT>
</text></ref><ref id="CR17"><text><SENT sid="260" pm="."><plain>17TeschendorffAEMenonUGentry-MaharajARamusSJWeisenbergerDJShenHCampanMNoushmehrHBellCGMaxwellAPAge-dependent dna methylation of genes that are suppressed in stem cells is a hallmark of cancerGenome Res2010204440610.1101/gr.103606.109<?supplied-pmid 20219944?>20219944 </plain></SENT>
</text></ref><ref id="CR18"><text><SENT sid="261" pm="."><plain>18ZhangXHuYJusticeACLiBWangZZhaoHKrystalJHXuKDna methylation signatures of illicit drug injection and hepatitis c are associated with hiv frailtyNat Commun201781224310.1038/s41467-017-02326-1<?supplied-pmid 29269866?>29269866 </plain></SENT>
</text></ref><ref id="CR19"><text><SENT sid="262" pm="."><plain>19BenjaminiYHochbergYControlling the false discovery rate: a practical and powerful approach to multiple testingJ R Stat Soc Ser B Methodol1995571289300 </plain></SENT>
</text></ref><ref id="CR20"><text><SENT sid="263" pm="."><plain>20FarkasSAMilutin-GašperovNGrceMNilssonTKGenome-wide dna methylation assay reveals novel candidate biomarker genes in cervical cancerEpigenetics201381112132510.4161/epi.26346<?supplied-pmid 24030264?>24030264 </plain></SENT>
</text></ref><ref id="CR21"><text><SENT sid="264" pm="."><plain>21KudelaEHolubekovaVFarkasovaADankoJDetermination of malignant potential of cervical intraepithelial neoplasiaTumor Biol20163721521510.1007/s13277-015-4677-3 </plain></SENT>
</text></ref><ref id="CR22"><text><SENT sid="265" pm="."><plain>22YaziciogluMNMonaldiniLChuKKhaziFRMurphySLHuangHMargaritisPHighKACellular localization and characterization of cytosolic binding partners for Gla domain-containing proteins PRRG4 and PRRG2J Biol Chem201328836259081410.1074/jbc.M113.484683<?supplied-pmid 23873930?>23873930 </plain></SENT>
</text></ref><ref id="CR23"><text><SENT sid="266" pm="."><plain>23DevosseTGuillabertAD’HaeneNBertonADe NadaiPNoelSBraitMFranssenJ-DSozzaniSSalmonIParmentierMFormyl peptide receptor-like 2 is expressed and functional in plasmacytoid dendritic cells, tissue-specific macrophage subpopulations, and eosinophilsJ Immunol2009182849748410.4049/jimmunol.0803128<?supplied-pmid 19342677?>19342677 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
